Pfizer Inc. (NYSE:PFE) Shares Sold by Evermay Wealth Management LLC

Evermay Wealth Management LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 28.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,459 shares of the biopharmaceutical company’s stock after selling 5,458 shares during the period. Evermay Wealth Management LLC’s holdings in Pfizer were worth $357,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of PFE. Quarry LP acquired a new stake in shares of Pfizer during the 2nd quarter valued at $31,000. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Pfizer by 60.3% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 583,600 shares of the biopharmaceutical company’s stock worth $16,329,000 after purchasing an additional 219,600 shares during the last quarter. Central Pacific Bank Trust Division grew its holdings in Pfizer by 71.8% during the third quarter. Central Pacific Bank Trust Division now owns 9,286 shares of the biopharmaceutical company’s stock valued at $269,000 after purchasing an additional 3,880 shares during the last quarter. Czech National Bank raised its holdings in Pfizer by 6.9% in the 3rd quarter. Czech National Bank now owns 1,154,366 shares of the biopharmaceutical company’s stock worth $33,407,000 after acquiring an additional 74,737 shares during the period. Finally, Canandaigua National Bank & Trust Co. boosted its stake in Pfizer by 23.6% during the 3rd quarter. Canandaigua National Bank & Trust Co. now owns 235,277 shares of the biopharmaceutical company’s stock valued at $6,809,000 after purchasing an additional 44,957 shares during the period. 68.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Citigroup cut their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday. Guggenheim cut their price target on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, UBS Group decreased their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Trading Down 1.5 %

NYSE:PFE opened at $26.51 on Friday. The firm has a market cap of $150.20 billion, a P/E ratio of 35.82, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The firm’s fifty day moving average is $26.27 and its 200-day moving average is $27.87.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the previous year, the company posted ($0.17) earnings per share. The company’s quarterly revenue was up 31.2% on a year-over-year basis. Equities analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.49%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is currently 232.44%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.